The Association of the British Pharmaceutical Industry (ABPI) welcomes its newest member Santen UK.
The UK subsidiary of the Japanese specialist ophthalmic pharmaceutical company was established in November 2014 and is the latest franchise in its European presence which also includes Germany, France and Italy as well as north, central and east Europe.
Santen, based in St Albans, is a welcomed addition to the full company membership of the ABPI that includes small, medium and large research-based biopharmaceutical companies operating in the UK.
Welcoming Santen to the ABPI, Samantha Ogden, Chief of Staff and Operations, said: "It is hugely encouraging for the industry and the wider UK economy that biopharmaceutical companies continue to see the UK as a great place to invest and do business and we are looking forward to working with colleagues at Santen, alongside the rest of our membership, to ensure that this remains the case for the future."
Craig Wallace, General Manager for Santen UK and Ireland, added: "As we build on our long and distinguished history to develop our presence in the UK we are pleased to be joining such a proactive and influential trade body that works effectively for and on behalf of its membership. We look forward to working with the ABPI and fellow members for the benefit of the UK pharmaceutical industry."
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
As a specialty company dedicated to the ophthalmic and anti-rheumatic fields, Santen carries out the research, development, sales, and marketing of pharmaceuticals. The company has 15 bases in 12 countries globally and delivers products to consumers in more than 50 countries. In Japan, Santen holds the No. 1 share in the prescription ophthalmic pharmaceutical market. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs.